The same was true for the HF-HRV (M = 2021; SD = 3515 of patients on kallikrein inhibitors, and M = 1093 and SD = 1505 in patients without this treatment; U = 3.00; p = 0.8) (Table 3). This evidence concerns the gene KLK4 and hydrops fetalis.